Elicio Therapeutics: Initiation of a Phase 1/2 Trial of ELI-002 in KRAS-Driven Cancers – CBI
Homepage /  Press Release /  Elicio Therapeutics: Initiation of a Phase 1/2 Trial of ELI-002 in KRAS-Driven Cancers

Press Release

Elicio Therapeutics: Initiation of a Phase 1/2 Trial of ELI-002 in KRAS-Driven Cancers